Genentech Inc. - About Lung Cancer

OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva(R) (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment ...